Edesa Biotech (EDSA) 10-Q2018 Q1 Quarterly report

Filed: 7 Feb 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: accurate, afforded, America, bid, byproduct, calendar, center, chosen, clarification, codified, compliance, consideration, consolidatedfinancial, cumulative, Customerswhich, deadline, deficiency, delist, delisted, Delisting, demonstrate, desire, difficult, distribute, drug, engineering, ensure, evoke, expiry, feet, flexibility, full, grace, hand, letter, LLC, mix, modified, national, negative, negatively, Neostell, North, notification, notifying, oceanfront, onthe, opening, order, Park, passed, performanceobligation, principle, promised, quotation, regain, resolve, retained, retrospective, retrospectively, robust, Rule, saleable, seawater, shipped, space, square, staffing, standard, Step, technical, timeline, Today, twelve

Removed: ability, achievement, Adagloxad, addition, afterDecember, applied, arise, awarded, broker, chair, chemistry, classification, closed, collectively, combined, concurrent, conducted, confidentiality, controlled, create, creditable, customary, deciding, delayed, delivery, demand, denominated, derivative, detailed, determining, disposal, District, dollar, doubt, establish, expired, extension, feasibility, fee, FIFO, filing, flow, footnote, fulfilling, fully, growing, half, headquartered, Hedging, higher, immunogenicity, impacted, industry, ingredient, initiated, injectable, investing, launch, LIFO, manager, Marketplace, member, met, negotiate, noncash, nondilutive, obtaining, optimize, organization, originally, OTCQB, Oxnard, partner, pay, placement, point, positioning, Practical, preclinical, predictable, present, private, proceed, processing, profit, prosecution, prospectively, purification, qualification, realize, realized, reclassified, reference, regional, reimburse, reimbursed, reimbursement, Rescission, reserved, responsibility, retail, SBOTF, scalable, seek, selling, Simolenin, Simplification, Simplifying, site, source, specific, stability, stimulate, submittal, substantial, sufficient, summary, sustainable, Taiwanese, Tier, toxicity, traceable, transportation, treatment, TSX, unit, variety, warrant, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

EDSA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Stellar Biotechnologies, Inc. (the Company) for the quarter ended December 31, 2017 (the Report), as filed with the Securities and Exchange Commission on the date hereof, I, Frank R. Oakes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 7, 2018	By:	/s/ Frank R. Oakes
		Frank R. Oakes
		President and Chief Executive Officer
		(Principal Executive Officer)